Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 47M | 32M | 19M |
| Gross Profit | 36M | 24M | 15M |
| Operating Income | -26M | -15M | -11M |
| EBITDA | -26M | -12M | -10M |
| Net Income | -40M | -16M | -13M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$18.55
+3.23% today
Window Change
+23.26%
Window
Jul 31, 2025 → Jun 18, 2026
Coverage: 222 bars · Jul 31, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shoulder Innovations, Inc. (SI) is a Healthcare stock with a market cap of $280.00M and listed on NYSE. The stock last traded around $18.55 and up 23.3% across the available one-year price window (Jul 31, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +49.6%, EPS growth of +99.4%, a dividend yield of 0.0%. What stands out right now is revenue +49.6%, EPS +99.4%, free cash flow -98.4% with operating margin -55.6% and ROIC -14.8%. Valuation sits in the middle of the pack at price/sales 5.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SI Max Drawdown
-31.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$19.3M
-39.1% YoY
FY Net Income
-$12.7M
+19.0% YoY
Free Cash Flow
-$15.9M
+12.5% YoY
Revenue Growth
+49.6%
EPS Growth
+99.4%
Gross Margin
76.5%
Net Margin
-85.3%
Income statement
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 47M | 32M | 19M |
| Gross Profit | 36M | 24M | 15M |
| Operating Income | -26M | -15M | -11M |
| EBITDA | -26M | -12M | -10M |
| Net Income | -40M | -16M | -13M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash & Equivalents | 27M | 6M | 6M |
| Total Assets | 170M | 43M | 54M |
| Total Liabilities | 15M | 98M | 94M |
| Shareholder Equity | 155M | 20M | 35M |
| Total Debt | 15M | 15M | 14M |
| Net Debt | -12M | 9M | 8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13M
+7.1% YoY
Capital Expenditures
3M
+31.6% YoY
Free Cash Flow
16M
+12.5% YoY
Key ratios
Gross Margin
76.5%
Operating Margin
-55.6%
Net Margin
-85.3%
ROE
-89.5%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.